Merck & Co., Inc. (NYSE:MRK) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lowered its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 1.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 7,158,625 shares of the company’s stock after selling 71,103 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Merck & Co., Inc. were worth $780,433,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. NTV Asset Management LLC boosted its holdings in shares of Merck & Co., Inc. by 0.3% in the 4th quarter. NTV Asset Management LLC now owns 26,534 shares of the company’s stock valued at $2,893,000 after purchasing an additional 80 shares during the last quarter. SRS Capital Advisors Inc. boosted its holdings in shares of Merck & Co., Inc. by 1.6% in the 4th quarter. SRS Capital Advisors Inc. now owns 5,037 shares of the company’s stock valued at $549,000 after purchasing an additional 81 shares during the last quarter. Endowment Wealth Management Inc. boosted its holdings in shares of Merck & Co., Inc. by 3.2% in the 4th quarter. Endowment Wealth Management Inc. now owns 2,637 shares of the company’s stock valued at $288,000 after purchasing an additional 81 shares during the last quarter. Onyx Bridge Wealth Group LLC boosted its holdings in shares of Merck & Co., Inc. by 0.4% in the 4th quarter. Onyx Bridge Wealth Group LLC now owns 19,166 shares of the company’s stock valued at $2,089,000 after purchasing an additional 83 shares during the last quarter. Finally, Per Stirling Capital Management LLC. boosted its holdings in shares of Merck & Co., Inc. by 2.4% in the 4th quarter. Per Stirling Capital Management LLC. now owns 3,691 shares of the company’s stock valued at $402,000 after purchasing an additional 85 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Ratings Changes

MRK has been the topic of a number of research analyst reports. Wells Fargo & Company lifted their price target on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a report on Wednesday, March 27th. Truist Financial lifted their price target on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a report on Friday, April 26th. Argus upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday. Societe Generale lowered shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price on the stock. in a report on Monday, March 11th. Finally, Berenberg Bank lifted their target price on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a report on Monday, April 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $133.00.

View Our Latest Stock Report on MRK

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK traded up $0.16 during trading on Friday, reaching $130.68. 1,614,584 shares of the company’s stock traded hands, compared to its average volume of 8,043,360. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99. Merck & Co., Inc. has a 12 month low of $99.14 and a 12 month high of $133.10. The company has a 50 day moving average of $128.53 and a 200-day moving average of $121.14. The stock has a market capitalization of $330.99 billion, a P/E ratio of 145.29, a price-to-earnings-growth ratio of 1.67 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.21 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. Merck & Co., Inc.’s revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.40 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 8.64 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, July 8th. Shareholders of record on Monday, June 17th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 2.36%. The ex-dividend date is Monday, June 17th. Merck & Co., Inc.’s payout ratio is 342.22%.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.